Barbara:
You asked why Merck cannot make a better, quicker, acting Sinemet CR.
This is not a very satisfactory answer but is the best I have to offer:
Merck scientists really tried quite hard, for a considerable number of
years, to come up with a quick responding long acting form of Sinemet CR.
Their goal was to find a levodopa perparation that would find its way to
the brain as quickly as it does in the standard Sinemet tablet and at the
same time last all day; in other words a quick acting once a day tablet.
What you have available ri
ght now is the best that some of the best pharmaceutical researchers were
able to develop.
Merck then and DuPont Merck now both want to provide the best Sinemet CR
delivery system possible and if something new comes from the research
laboratories, you will have the chance to use it.
Best regards this holiday season to you and everyone else in the PARKINSN
Net.
Joe Irr ([log in to unmask])
